MGC Pharma has launched a new app designed to collect patient data while under the supervision of a medicinal practitioner with the goal of further evaluating the usage, dosage and efficacy of CannEpil as a treatment.
CannEpil is a phytocannabinoid product developed for the treatment of drug-resistant epilepsy.
The CannEpil app also gives medical professionals access to MGC’s International Library of Cannabinoids (ILC) as part of its collaboration with the Royal Melbourne Institute of Technology (RMIT). MGC describes the ILC as a world-first centralised platform designed to compile the diverse range of existing data on the therapeutic benefits of medicinal cannabis.
MGC Pharmaceutical co-founder and managing director Roby Zomer said: “Data is extremely important in the healthcare industry and is something that is not widely collected or stored at this time within the medicinal cannabis sector.
“The app and the ILC provides the medical community with access to what doctors need the most in order to start adopting and implementing phytocannabinoid treatments into their treatment toolkit: validated patient-based data, collected according to globally recognised standards, available for efficient comparative medical decision making and prescription.
“The use of the data we collect in this way is designed to aid the phytocannabinoid industry as a whole and to fill the void where there has been a significant lack of knowledge and data, responsibly collected and maintained.
“MGC believes this data will be invaluable for future product development, health and safety studies, and much more.
“While the CannEpil app focuses on patient outcomes for a specific formulation, ILC collects data for all different types of cannabis strains and their efficacy for treating various disorders,” said Zomer.